2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Monday, November 11, 2019

9:00AM-11:00AM: Abstract Number: 1220

How Are Flares Reported in Long-term Gout Clinical Trials? A Content Analysis of Randomized Controlled Trials

Metabolic & Crystal Arthropathies Poster II: Clinical Trials & Basic Science

9:00AM-11:00AM: Abstract Number: 1233

Identification and Characterization of a Novel Dysfunction Variant p.I242T in ABCG2 Transporter in a Family with Early-onset Hyperuricamia and Gout

Metabolic & Crystal Arthropathies Poster II: Clinical Trials & Basic Science

9:00AM-11:00AM: Abstract Number: 1090

Identification of a Distinct Intestinal Behçet’s Disease Cluster in Japan: A Nationwide Retrospective Observational Study

Epidemiology & Public Health Poster II: Spondyloarthritis & Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 991

Identification of Citrullinated Peptide Specific T-cells in Humanized Mice Immunized with Citrullinated Peptides

RA – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 992

Identification of CJ-15314, a Novel Highly Selective JAK1 Inhibitor, for the Treatment of Rheumatoid Arthritis

RA – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 1051

Identification of Differential Chromatin Accessibility Using ATAC-seq in a Novel 3D Tissue Culture System of Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1016

Identification of Differentially Expressed Genes and Signaling Pathways in Systemic Lupus Erythematosus by Integrated Bioinformatics Analysis

SLE – Etiology & Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 1073

Identification of Distinct Pro-Fibrotic Monocyte and Macrophage Subsets in Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1290

Identification of Distinctive Interferon Gene Signatures in Different Types of Inflammatory Myopathy

Muscle Biology, Myositis & Myopathies Poster II

9:00AM-11:00AM: Abstract Number: 1342

Identification of Heterogenous Treatment Response Trajectories to anti-IL6 Receptor Treatment in Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster II: Treatments, Outcomes, & Measures

9:00AM-11:00AM: Abstract Number: 958

Identification of IFN-γ-producing Effector B Cells in Humans: Their Relevance to the Pathogenesis of Systemic Lupus Erythematosus

B Cell Biology & Targets In Autoimmune & Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 1067

Identification of miRNAs in Systemic Sclerosis Based on Activity and Network Analysis

Systemic Sclerosis & Related Disorders – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 976

Identification of Novel Genes Associated with Dysregulation of B Cells in Patients with Primary Sjögren’s Syndrome

B Cell Biology & Targets In Autoimmune & Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 1746

Identifying Additional Risk Factors for Arterial and Venous Thrombosis Among Pediatric Antiphospholipid Antibodies Carriers

Pediatric Rheumatology – ePoster II: SLE, Juvenile Dermatomyositis, & Scleroderma

9:00AM-11:00AM: Abstract Number: 964

Identifying Jo-1-Specific B Cells in the Primary Immune Repertoire in Idiopathic Inflammatory Myopathies

B Cell Biology & Targets In Autoimmune & Inflammatory Disease Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].